BMY’s 2025 Market Dance: Down -1.23% – Time to Invest?

A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. This year’s metric has recorded a Price decrease of -1.23%. However, over the past six months, we’ve seen a stronger performance of -19.21%. The price of BMY leaped by -1.98% over the last 30 days. And in the last five days, it has surged by 1.17%.

The stock price for Bristol-Myers Squibb Co (BMY) currently stands at $45.93. The stock experienced a substantial increase in the last session, hitting $68.0 after starting at $45.93. The stock’s lowest price was $34.0 before closing at $45.95.

Bristol-Myers Squibb Co experienced a rather shaky stock market performance. The highest value in the past year was recorded at $63.33 on 03/11/25 and the lowest value was $42.96 on 07/31/25.

52-week price history of BMY Stock

Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Bristol-Myers Squibb Co’s current trading price is -27.48% away from its 52-week high, while its distance from the 52-week low is 6.91%. The stock’s price range during this time has been between $42.96 and $63.33. The trading volume for the Healthcare sector company’s shares reached about 8.66 million for the day, which was lower than the average daily volume of 14.03 million over the last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Bristol-Myers Squibb Co (BMY) has experienced a quarterly decline of -1.12% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 93.49B and boasts a workforce of 34100 employees.

Bristol-Myers Squibb Co: Analysts’ Ratings Unveiled

As of right now, 4 analysts are rating Bristol-Myers Squibb Co as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 19 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 49.42, with a change in price of -13.97. Similarly, Bristol-Myers Squibb Co recorded 14,450,688 in trading volume during the last 100 days, posting a change of -23.32%.

BMY’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BMY stands at 2.92. Similarly, the long-term debt-to-equity ratio is also 2.64.

BMY Stock Stochastic Average

Today’s raw stochastic average for Bristol-Myers Squibb Co over the last 50 days is 38.08%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 47.03%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 44.13% and 40.05%, respectively.

Invest Chronicle
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.